Skip to content

Real-Time Synchronous Aspiration vs Staged Radiofrequency Ablation for Cyst-Dominant Thyroid Nodules

Retrospective Comparative Analysis of Ultrasound-Guided Real-Time Synchronous Aspiration versus Staged Radiofrequency Ablation for Cyst-Dominant Thyroid Nodules

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124555
Enrollment
Unknown
Registered
2026-05-13
Start date
2026-05-13
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

predominantly cystic thyroid nodules, PCTN

Interventions

Observation Group:None

Sponsors

The Affiliated Provincial Hospital of Fuzhou University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of predominantly cystic thyroid nodules (Thyroid Imaging Reporting and Data System [TIRADS] category 2 or 3) confirmed by ultrasound, with cystic components accounting for 50% to 90%; 2. Maximum nodule diameter >= 2 cm, accompanied by cervical compression symptoms (such as dysphagia, dyspnea) or cosmetic needs; 3. Normal coagulation function (indicators such as prothrombin time and activated partial thromboplastin time within the normal reference range); 4. No history of neck surgery; 5. Refusal of surgical resection or inability to tolerate surgery due to physical conditions.

Exclusion criteria

Exclusion criteria: 1. Pure cystic nodules (cystic components > 90%), nodules with solid components > 10%, or nodules suggestive of suspected malignancy on ultrasound (TIRADS category 4 or above); 2. Complicated with hyperthyroidism or hypothyroidism that was not effectively controlled; 3. Nodules located too deeply (e.g., behind the sternum, protruding into the mediastinum), leading to a significantly increased risk of ablation; 4. Recent use of anticoagulant drugs (such as warfarin, rivaroxaban, etc.) without discontinuing the drugs as required, presence of severe coagulation disorders, or inability to cooperate with the operation; 5. Loss to follow-up or incomplete clinical data.

Design outcomes

Primary

MeasureTime frame
Total Complication Rate;Treatment Success Rate;Nodule Volume Reduction Ratio (VRR);

Secondary

MeasureTime frame
Cosmetic Score;Visual Analogue Scale (VAS) Score for Compressive Symptoms;

Countries

China

Contacts

Public ContactYang Jianchuan

The Affiliated Provincial Hospital of Fuzhou University

danny83616@sina.com+86 10 1234567

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026